Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Autologous Platelet-Rich Plasma on Promoting Bone Regeneration in Maxillary and Mandibular Fractures: A Randomized Controlled Trial

NCT07930026 is registered in ClinicalTrials.gov with CMH Lahore Medical College and Institute of Dentistry as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07930026 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Autologous Platelet-Rich Plasma on Promoting Bone Regeneration in Maxillary and Mandibular Fractures: A Randomized Controlled Trial
Lead sponsor
CMH Lahore Medical College and Institute of Dentistry
Phase
Not applicable
Overall status
Recruiting
Start date
June 2, 2026
Completion date
December 11, 2026
Enrollment
40 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

Arms

As registered; 2 arms.

  • PRP + Miniplate Fixation ExperimentalAutologous Platelet-Rich Plasma (PRP)

    Patients undergo open reduction and internal fixation of the maxillary or mandibular fracture under general anaesthesia with two titanium miniplates and screws. Autologous platelet-rich plasma is prepared from 12 ml of the patient's venous blood by double centrifugation, activated with calcium chloride and bovine thrombin, and applied as a gel along the fracture line before wound closure. Postoperatively, patients receive antibiotics and anti-inflammatory medication for one week.

  • Miniplate Fixation Alone Active comparatorOpen Reduction and Internal Fixation With Titanium Miniplates

    Patients undergo open reduction and internal fixation of the maxillary or mandibular fracture under general anaesthesia with two titanium miniplates and screws, identical to the experimental arm, without application of platelet-rich plasma. Postoperatively, patients receive antibiotics and anti-inflammatory medication for one week.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Bone Density at the Fracture Site 6 months after surgery

    Mean bone density in Hounsfield units (HU) measured on cone-beam computed tomography (CBCT) within a 3 x 2.5 mm rectangular region of interest placed across the fracture line above the upper miniplate, using Planmeca software. Measurements are made by an assessor blinded to group allocation. Higher values indicate greater bone mineralization.

Lead sponsor's other trials

CMH Lahore Medical College and Institute of Dentistry, most recent start first.

Similar trials

Same condition (Maxillary Fractures) and phase, most recent start first.